FDA Approves Astellas' Vaprisol(R) For The Treatment Of Hypervolemic Hyponatremia

FDA Approves Astellas' Vaprisol(R) For The Treatment Of Hypervolemic Hyponatremia
Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vaprisol(R) (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist, for the intravenous treatment of hypervolemic hyponatremia in hospitalized patients. Vaprisol, discovered and developed by Astellas, is the first drug specifically indicated for the treatment of both euvolemic and hypervolemic hyponatremia, potentially life-threatening conditions that occur when the body's blood sodium level falls significantly below normal. Vaprisol was approved by the FDA as a treatment for euvolemic hyponatremia in December 2005, and has been marketed by Astellas since April 2006.